CAR T-cell therapy for pancreatic cancer.
J Surg Oncol
; 116(1): 63-74, 2017 Jul.
Article
in En
| MEDLINE
| ID: mdl-28346697
ABSTRACT
Chimeric antigen receptor (CAR) T-cell therapy utilizes genetic engineering to redirect a patient's own T cells to target cancer cells. The remarkable results in hematological malignancies prompted investigating this approach in solid tumors such as pancreatic cancer. The complex tumor microenvironment, stromal hindrance in limiting immune response, and expression of checkpoint blockade on T cells pose hurdles. Herein, we summarize the opportunities, challenges, and state of knowledge in targeting pancreatic cancer with CAR T-cell therapy.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pancreatic Neoplasms
/
T-Lymphocytes
/
Immunotherapy, Adoptive
Limits:
Humans
Language:
En
Journal:
J Surg Oncol
Year:
2017
Document type:
Article